{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:49:58Z","timestamp":1794275398752,"version":"4.9.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jacc.2021.08.051","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T17:34:18Z","timestamp":1635183258000},"page":"1817-1830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["New Therapies for Lowering Triglyceride-Rich Lipoproteins"],"prefix":"10.1016","volume":"78","author":[{"given":"Robert S.","family":"Rosenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleesha","family":"Shaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenliang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jacc.2021.08.051_bib1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10557-021-07168-0","article-title":"Genetics of triglyceride-rich lipoproteins guide identification of pharmacotherapy for cardiovascular risk reduction","volume":"35","author":"Shaik","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"issue":"9","key":"10.1016\/j.jacc.2021.08.051_bib2","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"78","author":"Virani","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.08.051_bib3","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2337\/dbi19-0007","article-title":"Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease","volume":"69","author":"Chait","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.jacc.2021.08.051_bib4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/clinchem\/hvaa296","article-title":"Triglyceride-rich lipoprotein remnants and cardiovascular disease","volume":"67","author":"Duran","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2021.08.051_bib5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1515\/cclm-2019-1253","article-title":"Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM","volume":"58","author":"Langlois","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jacc.2021.08.051_bib6","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","article-title":"Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation","volume":"128","author":"Varbo","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.08.051_bib7","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1016\/j.jacc.2021.04.059","article-title":"Triglycerides and residual atherosclerotic risk","volume":"77","author":"Raposeiras-Roubin","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.08.051_bib8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1194\/jlr.M700505-JLR200","article-title":"Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation","volume":"50","author":"Wang","year":"2009","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2021.08.051_bib9","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/01.CIR.0000117403.64398.53","article-title":"Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol","volume":"109","author":"Shin","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.08.051_bib10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/clinchem\/hvaa290","article-title":"Very low-density lipoprotein cholesterol may mediate a substantial component of the effect of obesity on myocardial infarction risk: the Copenhagen general population study","volume":"67","author":"Johansen","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2021.08.051_bib11","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ana.25432","article-title":"Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population","volume":"85","author":"Varbo","year":"2019","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jacc.2021.08.051_bib12","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.jacc.2020.10.008","article-title":"Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease","volume":"76","author":"Casta\u00f1er","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.08.051_bib13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.08.051_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehab432","article-title":"Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study","author":"Quispe","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.08.051_bib15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jacc.2018.04.050","article-title":"Remnant-like particle cholesterol, low-density lipoprotein triglycerides, and incident cardiovascular disease","volume":"72","author":"Saeed","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.08.051_bib16","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.jacc.2020.02.059","article-title":"Triglyceride-rich lipoprotein cholesterol, small dense ldl cholesterol, and incident cardiovascular disease","volume":"75","author":"Duran","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.08.051_bib17","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1016\/j.jacc.2020.09.610","article-title":"VLDL cholesterol accounts for one-half of the risk of myocardial infarction associated with apoB-containing lipoproteins","volume":"76","author":"Balling","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.08.051_bib18","article-title":"Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study","author":"Hussain","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2021.08.051_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241993","article-title":"Association of small, dense LDL-cholesterol concentration and lipoprotein particle characteristics with coronary heart disease: a systematic review and meta-analysis","volume":"15","author":"Liou","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2021.08.051_bib20","article-title":"Small dense low-density lipoprotein cholesterol is the most atherogenic lipoprotein parameter in the prospective framingham offspring study","volume":"10","author":"Ikezaki","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2021.08.051_bib21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jacl.2018.10.006","article-title":"Severe hypertriglyceridemia is primarily polygenic","volume":"13","author":"Dron","year":"2019","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2021.08.051_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3945\/an.111.000893","article-title":"Omega-3 fatty acids EPA and DHA: health benefits throughout life","volume":"3","author":"Swanson","year":"2012","journal-title":"Adv Nutr"},{"key":"10.1016\/j.jacc.2021.08.051_bib23","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bbalip.2011.10.011","article-title":"Fish oil--how does it reduce plasma triglycerides?","volume":"1821","author":"Shearer","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jacc.2021.08.051_bib24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","article-title":"Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals","volume":"3","author":"Aung","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2021.08.051_bib25","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.08.051_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1811403","article-title":"Marine n-3 fatty acids and prevention of cardiovascular disease and cancer","volume":"380","author":"Manson","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.08.051_bib27","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n-3 fatty acid supplements in diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.08.051_bib28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.08.051_bib29","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2021.08.051_bib30","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1161\/CIRCULATIONAHA.119.041998","article-title":"Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic Classes: a systematic review and meta-regression analysis of randomized controlled trials","volume":"140","author":"Marston","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.08.051_bib31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.chemphyslip.2018.01.002","article-title":"Eicosapentaenoic acid and docosahexaenoic acid have distinct membrane locations and lipid interactions as determined by X-ray diffraction","volume":"212","author":"Sherratt","year":"2018","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.jacc.2021.08.051_bib32","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1016\/j.bbamem.2016.10.002","article-title":"Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes","volume":"1858","author":"Mason","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jacc.2021.08.051_bib33","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.bpj.2012.06.016","article-title":"Docosahexaenoic and eicosapentaenoic acids segregate differently between raft and nonraft domains","volume":"103","author":"Williams","year":"2012","journal-title":"Biophys J"},{"issue":"18 Suppl 1","key":"10.1016\/j.jacc.2021.08.051_bib34","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0735-1097(21)02811-4","article-title":"Higher docosahexaenoic acid levels lower the protective impact of eicosapentaenoic acid on long-term MACE in those with and without angiographic CAD","volume":"77","author":"Le","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.08.051_bib35","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehab555","article-title":"A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs","author":"Doi","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.08.051_bib36","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/dom.13744","article-title":"Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia","volume":"21","author":"Adiels","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2021.08.051_bib37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.08.051_bib38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.08.051_bib39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/ATVBAHA.118.311476","article-title":"Effects of APOC3 heterozygous deficiency on plasma lipid and lipoprotein metabolism","volume":"39","author":"Reyes-Soffer","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2021.08.051_bib40","doi-asserted-by":"crossref","first-page":"33997","DOI":"10.1074\/jbc.M113.495366","article-title":"Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets","volume":"288","author":"Larsson","year":"2013","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacc.2021.08.051_bib41","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.08.051_bib42","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/CIRCULATIONAHA.109.875807","article-title":"Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype","volume":"121","author":"Zheng","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.08.051_bib43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/MOL.0000000000000502","article-title":"Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism","volume":"29","author":"Ramms","year":"2018","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacc.2021.08.051_bib44","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1210\/jc.2003-032056","article-title":"Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity","volume":"89","author":"Cohn","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2021.08.051_bib45","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.2147\/DDDT.S224771","article-title":"Volanesorsen in the treatment of familial chylomicronemia syndrome or hypertriglyceridaemia: design, development and place in therapy","volume":"14","author":"Esan","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jacc.2021.08.051_bib46","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.08.051_bib47","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.08.051_bib48","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2021.08.051_bib49","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","article-title":"N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels","volume":"40","author":"Alexander","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.08.051_bib50","first-page":"E987","article-title":"RNA interference targeting hepatic angiopoietin-like protein 3 results in prolonged reductions in plasma triglycerides and LDL-C in human subjects","volume":"140","author":"Watts","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.08.051_bib51","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.08.051_bib52","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.08.051_bib53","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.molmet.2017.06.014","article-title":"ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase","volume":"6","author":"Chi","year":"2017","journal-title":"Mol Metab"},{"key":"10.1016\/j.jacc.2021.08.051_bib54","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1194\/jlr.M075689","article-title":"ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance","volume":"58","author":"Haller","year":"2017","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2021.08.051_bib55","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1194\/jlr.RA120000781","article-title":"Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids","volume":"61","author":"Chen","year":"2020","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2021.08.051_bib56","doi-asserted-by":"crossref","first-page":"33742","DOI":"10.1074\/jbc.M203215200","article-title":"ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase","volume":"277","author":"Shimizugawa","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacc.2021.08.051_bib57","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","article-title":"Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance","volume":"61","author":"Adam","year":"2020","journal-title":"J\u00a0Lipid Res"},{"issue":"5","key":"10.1016\/j.jacc.2021.08.051_bib58","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1161\/ATVBAHA.120.315204","article-title":"ANGPTL3 inhibition with evinacumab results in faster clearance of IDL and LDL apoB in patients with homozygous familial hypercholesterolemia","volume":"41","author":"Reeskamp","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2021.08.051_bib59","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","article-title":"Inhibition of angiopoietin-like protein 3 with a monoclonal\u00a0antibody reduces triglycerides in hypertriglyceridemia","volume":"140","author":"Ahmad","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.08.051_bib60","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2021.04.091","article-title":"Inhibition of angiopoietin-like protein 3 with evinacumab in patients with high and severe hypertriglyceridemia","volume":"78","author":"Ahmad","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.08.051_bib61","doi-asserted-by":"crossref","unstructured":"Rosenson RS, Gaudet D, Ballantyne C, et\u00a0al. A\u00a0phase 2 trial of the efficacy and safety of evinacumab in patients with severe hypertriglyceridemia. American College of Cardiology, Annual Meeting. 2021 Abstract 406-19.","DOI":"10.1016\/j.atherosclerosis.2021.06.901"},{"key":"10.1016\/j.jacc.2021.08.051_bib62","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.08.051_bib63","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia","volume":"41","author":"Gaudet","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.08.051_bib64","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","article-title":"Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study","volume":"206","author":"Pradhan","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2021.08.051_bib65","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.08.051_bib66","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721061155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721061155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:45:20Z","timestamp":1760017520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109721061155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":66,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0735109721061155"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2021.08.051","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Therapies for Lowering Triglyceride-Rich Lipoproteins","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2021.08.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}